Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

[ad_1] This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia…

Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program | BioSpace

[ad_1] – Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 – – Company’s intellectual property portfolio now…